Alx oncology reports fourth quarter and full year 2023 financial results and provides corporate update

South san francisco, calif., march 07, 2024 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update.
ALXO Ratings Summary
ALXO Quant Ranking